• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Analysis of virus-specific immunological response and clinical study trial for severe fever with thrombocytopenia syndrome(SFTS)

Research Project

Project/Area Number 16K09935
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Infectious disease medicine
Research InstitutionEhime University

Principal Investigator

Suemori Koichiro  愛媛大学, 医学部附属病院, 講師 (80571083)

Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
KeywordsSFTS / ファビピラビル / 異型リンパ球 / 重症熱性血小板減少症候群 / リンパ球 / T細胞クローン / サイトカイン
Outline of Final Research Achievements

Severe fever with thrombocytopenia syndrome (SFTS) was first reported as an novel tick-born infection with a high-fatality rate during 2011 in China.SFTS has been reported to be endemic in Japan since 2013. Pathopysiology and treatment of SFTS is unclear. Recently,it was reported that the anti-viral drug (favipiravir)inhibits the replication of SFTS virus in mouse model. Therefore, we have conducted a multicenter non-randomized trial,in which all patients with SFTS would receive favipiravir since 2016.The results implied the efficacy and safety of favipiravir against SFTS patients. On the other hand,we analyzed atypical lymphocytes in the peripheral blood in four SFTS patients at our hospital.Atypical lymphocytes resembled plasma cells morphologically and showed a CD19+CD38+ phenotype in flow cytometry. Our result suggests that specific immunological response occurs at SFTS infection.

Academic Significance and Societal Importance of the Research Achievements

致死率が高く、治療法が確立されていない重症熱性血小板減少症候群 (SFTS) に対するファビピラビルの有効性および安全性を世界で初めて臨床研究を行い検証した。近年、本邦におけるSFTSの真の死亡率は25~30%と指摘されているが、ファビピラビル投与群での死亡率は17.4%であり、ファビピラビルの有用性が示唆された。また本病態には支持療法の重要性も示唆され、当院における末梢血における異型リンパ球の表現型解析は、SFTSに対する特異的免疫応答を理解する上で重要な結果であり、病態把握や今後の支持療法の確立に役立つ可能性がある。

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (4 results)

All 2018 2017

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (3 results)

  • [Journal Article] Intractable Otitis Media Presenting as Falsely Positive for Proteinase 3-ANCA: A Case Report.2018

    • Author(s)
      Okada M, Ogawa H, Suemori K, Takagi D, Teraoka M, Yamada H, Hato N.
    • Journal Title

      The Journal of International Advanced Otology

      Volume: 2 Issue: 2 Pages: 337-340

    • DOI

      10.5152/iao.2018.4746

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] 重症熱性血小板減少症候群に対するファビピラビルの有効性と安全性の検討2018

    • Author(s)
      末盛浩一郎、東 太地、山中篤志、姫路大輔、川村昌史、葉久貴司、大毛宏喜、谷口智宏、今滝 修、高橋 徹, 石田正之、日高道弘、金子政彦、池田賢一、上国料千夏、石丸敏之、下島昌幸、河野 茂)、西條政幸、安川正貴
    • Organizer
      第88回日本感染症学会西日本地方会学術集会
    • Related Report
      2018 Annual Research Report
  • [Presentation] 重症熱性血小板減少症候群に対するファビピラビルの有効性と安全性の検討2018

    • Author(s)
      末盛浩一郎、東 太地、山中篤志、姫路大輔、川村昌史、葉久貴司、大毛宏喜、谷口智宏、今滝 修、高橋 徹, 石田正之、日高道弘、金子政彦、池田賢一、上国料千夏、垣花泰之、石丸敏之、竹中克斗、下島昌幸、河野 茂、西條政幸、安川正貴
    • Organizer
      第1回SFTS研究会・学術集会
    • Related Report
      2018 Annual Research Report
  • [Presentation] 重症熱性血小板減少症候群患者を対象としたファビピラビルの臨床試験2017

    • Author(s)
      東太地、内藤敦、山中篤志、姫路大輔、大窪秀直、川村昌史、末盛浩一郎、葉久貴司、田岡真理子、大毛宏喜、繁本憲文、梶原俊毅、谷口智宏、広沢秀泰、今滝修、下島昌幸、河野茂、西條政幸、安川正貴
    • Organizer
      第87回日本感染症学会西日本地方会学術集会
    • Related Report
      2017 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi